BPDCN Management: Tagraxofusp as a Bridge to Stem Cell Transplant
A brief review of the role of tagraxofusp as bridging therapy to stem cell transplant in patients diagnosed with blastic plasmacytoid dendritic cell neoplasm.
Tagraxofusp in BPDCN: Optimizing the Management of Adverse Events
Comprehensive discussion on the management of adverse events associated with tagraxofusp and how BPDCN care can be optimized in the setting of academic centers.
BCMA-Targeting Bispecific Antibodies in RRMM: Optimal Management of CRS
Focused discussion from a panel of key opinion leaders on the presence and management of cytokine release syndrome alongside BCMA-targeted therapy in relapsed/refractory MM.
Selecting and Sequencing BCMA-Targeting Bispecific Antibodies in Relapsed/Refractory MM
Shared insight from expert hematologist-oncologists on the real-world application of teclistamab to improve the management of multiple myeloma.
Metastatic CRC: Unmet Needs and Future Directions in Care
Closing out their review of the metastatic colorectal cancer treatment paradigm, expert panelists consider how the treatment armamentarium will continue to evolve.
FRESCO-2 Trial: Role of Fruquitinib in Refractory Metastatic CRC
Focused discussion on the FRESCO-2 trial, which analyzed use of fruquitinib in the refractory setting of metastatic colorectal cancer.
Physicians Should Factor Race, Ethnicity and Much More When Making Treatment Decisions in Contralateral Breast Cancer, Says Expert
The presence of several risk factors—such as age, race and mutation status—for contralateral breast cancer must be considered when making treatment decisions, according to an expert from the Mayo Clinic.
New Study Findings Will Generate Better Contralateral Breast Cancer Treatment Discussions Between Providers and Patients, Says Expert
Recent study findings related to risk factors for developing contralateral breast cancer may better influence treatment decisions between patients and physicians, according to a Mayo Clinic expert.
First-Line Therapy for Advanced RCC: Optimizing Adverse Event Management
A brief review of common adverse events inherent in the first-line management of advanced renal cell carcinoma and practical advice on how to mitigate treatment toxicity.
Overview of First-Line Treatment Options for Advanced RCC
Opening their discussion on the advanced renal cell carcinoma treatment landscape, experts Ulka N. Vaishampayan, MBBS, and Moshe Ornstein, MD, identify cornerstone first-line regimens.
Carriers of CHEK2 Mutations Have a 2-Fold Increased Risk for Contralateral Breast Cancer, Says Expert
An expert from the Mayo Clinic discusses findings from a population-based study concerning germline genetic mutations as risk factors of contralateral breast cancer.
Investigational Treatment Approach Effective, Safe and Inexpensive in a Type of Prostate Cancer, Says Expert
Thus far, findings from 2 trials show that treatment with bipolar androgen therapy is associated with several benefits in patients with castration-resistant prostate cancer, according to an expert from Sidney Kimmel Comprehensive Cancer Center.
HER2CLIMB: Role of Tucatinib in Treating HER2+ mBC With CNS Disease
A panel of expert oncologists highlight the use of the tucatinib, trastuzumab and capecitabine regimen that was investigated in the HER2CLIMB trial to manage patients with HER2+ breast cancer and brain metastases.
HER2+ Metastatic Breast Cancer: Role of Radiation Therapy in Managing CNS Disease
Expert perspectives on the respective role of radiation therapy to manage brain metastases in the setting of HER2+ breast cancer.
Many Unanswered Questions About Risks for Contralateral Breast Cancer Led to CARRIERS Study, Says Expert
An expert from the Mayo Clinic explains why he and his colleagues are researching risk factors for contralateral breast cancer in carriers of moderate-risk genes such as ATM, CHEK2, and PALB2.
Multiple Molecular Mechanisms May Drive Responses to Investigational Prostate Cancer Treatment, Expert Says
Investigators have observed that treatment with bipolar androgen therapy has suppressed at least one oncogene in patients with castration-resistant prostate cancer who derived a response to therapy.
Overview of BCMA-Targeting Bispecific Antibodies in Relapsed/Refractory MM
A broad perspective on the development of BCMA-targeted bispecific antibodies for patients with relapsed/refractory multiple myeloma.
Patient Case 1: Relapsed/Refractory MM Managed With Teclistamab
Centering discussion on two clinical cases of patients with relapsed/refractory multiple myeloma, expert panelists highlight the use of BCMA-targeted teclistamab in this setting.
‘Absolutely Important’ to Develop Better Ways to Predict Kidney Cancer Recurrence, Says Expert
Future research must address ways to improve the prediction of kidney cancer recurrence to better inform patients, says an expert from the Royal Free London NHS Foundation Trust.
Role of Immunotherapies in Microsatellite Stable Metastatic CRC
Shared insight on the potential role for immunotherapeutic agents in the setting of microsatellite stable metastatic colorectal cancer.
